Connor, Clark & Lunn Investment Management (CC&L)’s Astria Therapeutics ATXS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,160	Closed	-$198K	–	1398
2024 Q4	$198K	Buy	+22,160	New	+$235K	﹤0.01%	1327
2024 Q1	–	Sell	-13,484	Closed	-$104K	–	1520
2023 Q4	$104K	Sell	13,484 -28,586	-68%	-$158K	﹤0.01%	1321
2023 Q3	$314K	Sell	42,070 -10,593	-20%	-$90.3K	﹤0.01%	1126
2023 Q2	$439K	Buy	52,663 +15,144	+40%	+$175K	﹤0.01%	1021
2023 Q1	$499K	Buy	37,519 +19,875	+113%	+$269K	﹤0.01%	881
2022 Q4	$263K	Buy	+17,644	New	+$182K	﹤0.01%	1003
2021 Q2	–	Sell	-3,042	Closed	-$53K	–	971
2021 Q1	$53K	Buy	+3,042	New	+$55K	﹤0.01%	961

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ATXS Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Astria Therapeutics (ATXS) in Q1 2025, closing a stake of 22,160 shares — an estimated $198K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ATXS in Q1 2021 and held it in 7 quarters. The position peaked at $499K in Q1 2023. 115 funds tracked by Wall St. Rank hold ATXS as of Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Astria Therapeutics position as of Q1 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 22,160 Astria Therapeutics shares in Q1 2025, an estimated $198K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Astria Therapeutics in Q1 2021 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Astria Therapeutics position peaked at $499K in Q1 2023.
115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.